Allergan has announced plans to acquire privately-held Esprit Pharma in a $370 million all-cash deal that gives the former access to the overactive bladder therapy Sanctura.
In addition to Sanctura (trospium), a twice-a-day anticholinergic which Esprit licenses from Indevus Pharmaceuticals, Allergan is also getting hold of the extended-release, once-daily version of the drug.
The FDA recently granted approval for Sanctura XR and it is this version of the drug that could be a big earner for Allergan.
Source: PharmaTimes
No comments:
Post a Comment